Literature DB >> 15107976

[Significance of extracorporeal shock-wave therapy (ESWT) in plastic penile induration. Statement of the DGU].

W Weidner1, E W Hauck.   

Abstract

Entities:  

Mesh:

Year:  2004        PMID: 15107976     DOI: 10.1007/s00120-004-0581-y

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  6 in total

Review 1.  Extracorporeal shock wave therapy in orthopedics. Assessment of an emerging health technology.

Authors:  C Wild; M Khene; S Wanke
Journal:  Int J Technol Assess Health Care       Date:  2000       Impact factor: 2.188

2.  Extracorporal shock wave therapy in the treatment of Peyronie's disease. First results of a case-controlled approach.

Authors:  E W Hauck; B M Altinkilic; M Ludwig; G Lüdecke; I Schroeder-Printzen; C Arens; W Weidner
Journal:  Eur Urol       Date:  2000-12       Impact factor: 20.096

3.  Extracorporeal shock wave therapy for Peyronie's disease: exploratory meta-analysis of clinical trials.

Authors:  Ekkehard W Hauck; Ulrich O Mueller; Thomas Bschleipfer; Hans U Schmelz; Thorten Diemer; Wolfgang Weidner
Journal:  J Urol       Date:  2004-02       Impact factor: 7.450

Review 4.  Use of extracorporeal shock waves in the treatment of pseudarthrosis, tendinopathy and other orthopedic diseases.

Authors:  G Haupt
Journal:  J Urol       Date:  1997-07       Impact factor: 7.450

5.  Low-energy extracorporeal shock wave therapy for painful heel: a prospective controlled single-blind study.

Authors:  J D Rompe; C Hopf; B Nafe; R Burger
Journal:  Arch Orthop Trauma Surg       Date:  1996       Impact factor: 3.067

6.  A new biopsy technique to investigate Peyronie's disease associated histologic alterations: results with two different forms of therapy.

Authors:  Vincenzo Mirone; Ciro Imbimbo; Alessandro Palmieri; Nicola Longo; Ferdinando Fusco; Gianfranco Tajana
Journal:  Eur Urol       Date:  2002-09       Impact factor: 20.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.